Filer Snapshot

Commodore Capital LP

CIK 0001831942. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

102

Latest filing

16 Nov 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q3 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Largest parsed holding

RLAY

$216.6M reported value

Open holding

13D/G large stake

Mentari Therapeutics, Inc.

06 Nov 2026 · 5.6% ownership

Open 13D/G
Source: SEC Schedule 13D/G

SCHEDULE 13G/A filed on 16 Nov 2026 for CIK 0001831942.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$1.29B

Quarterly institutional holdings reported on Form 13F; not total AUM.

Forms 3/4/5 positions$431.49M

Reporting-owner positions with enough filing detail to estimate value.

Latest reported 13F value

13F
$1.29B

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Forms 3/4/5 position value

3/4/5
$431.49M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest 13F holdings

13F
RLAY ELVN ALKS ANRO SYRE
+15 moreAMLX LBRX DMRA COGT TYRA CLDX PHVS SRZN KRSA SGMT DFTX ADRX EDIT ENTX ATTO

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

AMAM VERA ELVN STSA

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

RLAY ELVN ALKS ANRO SYRE AMLX LBRX DMRA
+12 moreCOGT TYRA CLDX PHVS SRZN KRSA SGMT DFTX ADRX EDIT ENTX ATTO

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

RLAY ELVN MRUS COGT DFTX TYRA
+14 moreAVTX AMLX CLDX ANRO LBRX VRDN EYPT SGMT CDTX TERN EDIT NRIX RLMD SABS
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
444 Madison Avenue, 35 Th Floor, New York, NY, 10022
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Commodore Capital LP

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Quick read

  • Latest parsed 13F shows $1.29B across 37 reported holdings for Q3 2026.
  • Largest parsed 13F holding: RLAY at $216.6M.
  • 5 recent 13D/G stake rows found; top row is Mentari Therapeutics, Inc. at 5.6% ownership.
  • Forms 3/4/5 show insider context for AMAM worth $330.04M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 37 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 5 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q3 2026 - 16 Nov 2026

Top 5 concentration

48%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$615.08M

Compared with $1.29B total 13F value.

Top 5 net change

-$18.12M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: DMRA · Largest trim: AMLX

RLAY ELVN ALKS ANRO SYRE Other holdings

RLAY

16.8%

Relay Therapeutics Inc

$216.6M

ELVN

11.6%

Enliven Therapeutics Inc

$150.13M

ALKS

9%

Alkermes Plc

$116.51M

ANRO

5.4%

Alto Neuroscience Inc

$69.52M

SYRE

4.8%

Spyre Therapeutics Inc

$62.32M

13D/G large-stake context

Mentari Therapeutics, Inc.

06 Nov 2026 · Common Stock, par value $0.0001 per share

5.6%

ANTX

30 Sep 2026 · Common Stock, par value $0.00001 per share

9.9%

SGMT

30 Sep 2026 · Series A Common Stock, $0.0001 par value per share

7.6%

IFRX

30 Sep 2026 · Ordinary Shares, nominal value 0.12 EUR per share

6.3%

Forms 3/4/5 insider context

AMAM

23 Feb 2023 · 10% owner

$330.04M

VERA

10 Jan 2024 · 10% owner

$79.2M

ELVN

23 Feb 2023 · 10% owner

$21.93M

STSA

14 Nov 2022 · 10% owner

$325.7K

Latest update

What changed recently for Commodore Capital LP

New filing available

Latest 13F period: Q3 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

16 Nov 2026

Page type

Filer profile

Latest period

Q3 2026

Institutional portfolio context was refreshed from a 13F filing filed on 16 Nov 2026.

Benchmark Context

Benchmark context for this company

Commodore Capital LP has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q3 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

SEC filing record

CIK 0001831942 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
102
First seen
16 Feb 2021
Latest filing
16 Nov 2026
Entity
Company

Latest Filings

Showing the latest 12 of 102 SEC filings for Commodore Capital LP.

SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
16 Nov 2026
Reporting date
30 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
13 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
07 Oct 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .